Fresh analysis reveals that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Research printed in a prominent health publication demonstrates that while overweight individuals frequently drop a large proportion of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"People purchasing these medications must be aware of the potential of quick rebound weight gain when the medication is stopped," stated expert Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment mass within about a year and a half.
Comparing Therapies
The research, which reviewed 37 of trials involving over 9,000 of patients, compared the outcomes of these new drugs with other pills.
Researchers note that people who shed pounds through dieting generally have a slower weight regain—perhaps 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Doctors believe the mode of action of the jabs explains the heightened regain.
GLP-1 drugs copy a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than normal might result in the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating much more probable."
A Chronic Condition?
Medical guidelines suggest the injections for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts say that, considering the likelihood of relapse, the treatment should be considered ongoing.
This perspective is reinforced by drug manufacturers, who say that the findings "highlight the chronic character of excess weight," comparing it to managing conditions like diabetes.
User Accounts
People who have discontinued the jabs report a intense resurgence of appetite.
"I experienced something flipping and you become starving," recalled one woman.
This challenge is worsened if individuals have not developed lasting dietary or behavioural changes during therapy.
Widespread Use
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is higher among women than men.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a permanent solution and lasting health benefits relies on ongoing lifestyle changes.
